The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients

Overview of attention for article published in International Journal of Nephrology and Renovascular Disease, February 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 42 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 40 followers.

The cost-utility of treating anemia with continuous erythropoietin rec | IJNRD @DovePress https://t.co/BuqsX6W4MA

Reply Repost Favourite